While the gene targets of these drugs (PTSG2 and P2Y12) do not harbor variants specifically associated with CAD, some of the effector signaling molecules in the pathway (RHOA, ITGB5, and SH2B3) indeed have CAD associations, as described above. The gene discussed is SH2B3; the disease is coronary artery disorder.